Liver Disease
Conference Coverage
Short-course DAA therapy may prevent hepatitis transmission in transplant patients
BOSTON – While curing infection post transplant works, prevention would be preferable, investigators say.
Conference Coverage
Study spotlights severe NAFLD in lean patients
BOSTON – Lean patients with nonalcoholic fatty liver disease had almost twice the risk of advanced fibrosis as that of overweight and obese...
From the Journals
Level of hepatitis B core–related antigen is risk factor for hepatocellular carcinoma
Compared with patients whose HBcrAg level was less than 10 KU/mL, a level of 10-99 KU/mL was associated with a nearly threefold increase in risk...
From the Journals
Daily aspirin might cut risk of fibrosis progression
The researchers did not find a similar protective effect for NSAIDs other than aspirin.
Conference Coverage
Glecaprevir/pibrentasvir highly effective in HCV genotype 3, among others
BOSTON – Pangenotypic regimen may further progress toward elimination of hepatitis C, investigators say.
Conference Coverage
Duodenal mucosal resurfacing has metabolic effects in type 2 diabetes
BOSTON – Improvements in HbA1c and NASH biomarker favored the procedure over sham procedure in first-ever randomized, double-blind...
Conference Coverage
High doses of FXR agonist tropifexor reduce hepatic fat, serum ALT in patients with NASH
BOSTON – Mild pruritus, minor decreases in LDL cholesterol are notable adverse effects of treatment, similar to others in class.
Conference Coverage
Fenofibrate fights increased triglycerides in NASH
BOSTON – Patients with advanced fibrosis caused by NASH had limited increase in triglycerides after treatment with varying doses of fenofibrate....
From the Journals
Hepatitis C vaccine alters viral trajectory, but fails in chronic infection protection
BOSTON – First-ever randomized study does suggest changes in peak HCV RNA and an HCV RNA change after infection.
Conference Coverage
DUR-928 shows promise for alcoholic hepatitis
BOSTON – Among 15 patients with severe alcoholic hepatitis, 87% responded to treatment (Lille score less than 0.45).